SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

# Cemiplimab

| | |
|---|---|
| **Cat. No.:** | HY-P99203 |
| **CAS No.:** | 1801342-60-8 |
| **Target:** | PD-1/PD-L1 |
| **Pathway:** | Immunology/Inflammation |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |

## BIOLOGICAL ACTIVITY

**Description**

Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research[1][2].

**In Vivo**

Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) can increased the proportion of effector T cells in tumors and dLNs to reduce tumor growth by combined immunotherapy with REGN3767 in MC38.Ova tumor mice model[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|---|---|
| Animal Model: | Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells[2] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; five injections within 2 weeks |
| Result: | Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone.<br>Significantly increased the proportion of $CD4^+$ TILs in IFNγ and TNFα by combined immunotherapy with REGN3767. |

## REFERENCES

[1]. Michael R Migden, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351.

[2]. Elena Burova, et al. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18(11):2051-2062.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA